Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients

This study has been completed.
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00234689
First received: October 6, 2005
Last updated: January 28, 2008
Last verified: January 2008
  Purpose

Assessing the efficacy of Naltrexone as augmentation to SSRI in patients with OCD


Condition Intervention
Obsessive Compulsive Disorder
Drug: Naltrexone

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind

Resource links provided by NLM:


Further study details as provided by Sheba Medical Center:

Study Start Date: January 2002
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of OCD
  • Treatment with SSRI for at least 10 weeks with no response

Exclusion Criteria:

  • Suffering from any medical condition
  • treatment with opiates
  • chronic use of drugs
  • Hepatitis or other liver related diseases
  • Incapability to sign an informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00234689

Locations
Israel
Chaim Sheba Medical Center
Ramat-Gan, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Joseph Zohar, MD Tel Aviv University
Study Chair: Revital Amiaz, MD Tel Aviv University
  More Information

No publications provided

Responsible Party: Prof. Joseph Zohar, Chaim Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00234689     History of Changes
Other Study ID Numbers: SHEBA-99-1897-JZ-CTIL
Study First Received: October 6, 2005
Last Updated: January 28, 2008
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Compulsive Personality Disorder
Obsessive-Compulsive Disorder
Anxiety Disorders
Mental Disorders
Personality Disorders
Naltrexone
Central Nervous System Agents
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014